Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

SWI versus GRE-T2*: Assessing cortical superficial siderosis in advanced cerebral amyloid angiopathy.

Revue neurologique·2023
Same author

Lecanemab: Appropriate Use Recommendations.

The journal of prevention of Alzheimer's disease·2023
Same author

Discrepancies between tumor genomic profiling and germline genetic testing.

ESMO open·2022
Same author

Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer.

Asia-Pacific journal of clinical oncology·2020
Same author

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.

Allergy·2017
Same author

Neuroinflammation in the normal aging hippocampus.

Neuroscience·2015

相关实验视频

Updated: Jun 15, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 9, 2024

在冠状动脉支架干预中使用eptifibatide阻断血小板糖蛋白IIb/IIIa整体蛋白:ESPRIT试验:一种随机对照试验.

J C O'Shea1, G E Hafley, S Greenberg

  • 1Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705, USA.

JAMA
|May 23, 2001
PubMed
概括
此摘要是机器生成的。

在冠状动脉支架植入期间给予的eptifibatide治疗显著降低了6个月的死亡或心脏病发作风险. 这些早期观察到的好处在6个月的随访期内持续存在.

更多相关视频

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 6, 2020

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 13, 2018

相关实验视频

Last Updated: Jun 15, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 9, 2024

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 6, 2020

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 13, 2018

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 干预心脏病学 干预心脏病学

背景情况:

  • 该ESPRIT试验证明了eptifibatide在48小时30天内在冠状动脉支架植入后减少缺血并发症的有效性.
  • 这项研究旨在评估这些益处的长期持续性.

研究的目的:

  • 确定eptifibatide治疗的积极影响是否延伸到冠状动脉支架植入后的6个月.
  • 评估eptifibatide对缺血事件和死亡率的持续影响.

主要方法:

  • 一项随机,双盲,安慰剂对照试验的后续分析,该试验涉及2064名接受非紧急皮肤冠状动脉干预与支架植入的患者.
  • 患者接受了eptifibatide或安慰剂,死亡率,心肌梗塞 (MI) 和目标血管再血管化的复合率在6个月后被评估.

主要成果:

  • 治疗eptifibatide导致6个月的死亡或MI的复合率显著降低 (7.5%对11.5%,HR 0.63,P=.002).
  • 在eptifibatide组中,死亡,心脏病发作或目标血管再血管化的复合率也较低 (14.2%对18.3%,HR 0.75,P=.008).
  • 观察到的好处主要是在早期积累的,并保持在6个月的随访期间.

结论:

  • 在冠状动脉支架植入期间进行的辅助eptifibatide治疗提供长达6个月的持续临床益处.
  • 这些发现支持在接受非紧急冠状动脉支架的患者中继续使用eptifibatide,以减少长期缺血并发症.